ARS Pharmaceuticals (SPRY) Free Cash Flow (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Free Cash Flow of -$44.9 million for Q1 2026, down 3.36% sequentially from -$43.5 million in Q4 2025, and down 10.07% YoY from -$50.0 million in Q1 2025.
ARS Pharmaceuticals (SPRY) Free Cash Flow (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Free Cash Flow for 7 years, with the latest figure at -$44.9 million in Q1 2026.
- Quarterly Free Cash Flow fell 10.07% year-over-year to -$44.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$175.3 million (down 732.67% YoY) and the FY2025 annual result came in at -$171.2 million, down 1418.48% from the prior year.
- Free Cash Flow eased to -$44.9 million in Q1 2026 per SPRY's latest filing, from -$43.5 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $41.7 million in Q4 2024 and troughed at -$45.4 million in Q2 2025.
- A 5-year average of -$17.8 million and a median of -$14.7 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 338.45% in 2024, then plunged 530.36% in 2025.
- Over 5 years, Free Cash Flow stood at -$20.6 million in 2022, then grew by 15.2% to -$17.5 million in 2023, then soared by 338.45% to $41.7 million in 2024, then sank by 204.28% to -$43.5 million in 2025, then declined by 3.36% to -$44.9 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$44.9 million, -$43.5 million, and -$41.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -60.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -60.93 Mn |
| Jun 30, 2026 | -60.93 Mn |
| Mar 31, 2026 | -44.95 Mn |
| Mar 31, 2026 | -44.95 Mn |
| Dec 31, 2025 | -43.49 Mn |
| Dec 31, 2025 | -43.49 Mn |
| Sep 30, 2025 | -41.53 Mn |
| Sep 30, 2025 | -41.53 Mn |
| Jun 30, 2025 | -45.36 Mn |
| Jun 30, 2025 | -45.36 Mn |
| Mar 31, 2025 | -40.83 Mn |
| Mar 31, 2025 | -40.83 Mn |
| Dec 31, 2024 | 41.70 Mn |
| Dec 31, 2024 | 41.70 Mn |
| Sep 30, 2024 | -14.73 Mn |
| Sep 30, 2024 | -14.73 Mn |
| Jun 30, 2024 | -7.20 Mn |
| Jun 30, 2024 | -7.20 Mn |
| Mar 31, 2024 | -6.79 Mn |
| Mar 31, 2024 | -6.79 Mn |